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Clinical PerspectiveWhat Is New?ST‐segment--elevation myocardial infarction (STEMI) patients with hypo‐ and hyperkalemia had a higher risk of ventricular fibrillation (VF) before primary percutaneous coronary intervention (PPCI) compared with normokalemia, but the association may reflect a post‐resuscitation phenomenon as potassium was measured immediately before PPCI, hence after VF.For STEMI patients with in‐hospital VF before PPCI with a short time window between potassium measurement and VF, hypokalemia remained associated with VF compared with normokalemia.Among STEMI patients without VF before PPCI who had potassium measurements immediately before PPCI, hypokalemia was associated with VF during PPCI.What Are the Clinical Implications?Potassium disturbances among STEMI patients may increase the risk of VF before PPCI and subsequent death during acute ischemia.Further studies are needed to determine if correcting potassium disturbances will reduce the risk of VF before PPCI among patients with STEMI.

Introduction {#jah34752-sec-0008}
============

Coronary artery disease leading to myocardial infarction (MI) is the leading cause of sudden cardiac death.[1](#jah34752-bib-0001){ref-type="ref"}, [2](#jah34752-bib-0002){ref-type="ref"}, [3](#jah34752-bib-0003){ref-type="ref"}, [4](#jah34752-bib-0004){ref-type="ref"} Ventricular fibrillation (VF) complicating ST‐segment--elevation myocardial infarction (STEMI) occurs in ≈ 10% of patients[5](#jah34752-bib-0005){ref-type="ref"}, [6](#jah34752-bib-0006){ref-type="ref"} and remains a challenge for physicians as VF may be the first symptom of underlying cardiovascular disease.

Potassium disturbances are one of the most common electrolyte abnormalities.[7](#jah34752-bib-0007){ref-type="ref"} The role of potassium disturbances in the setting of MI has been studied, with a higher frequency of ventricular arrhythmias observed for low potassium levels (typically \<3.5 mmol/L).[8](#jah34752-bib-0008){ref-type="ref"}, [9](#jah34752-bib-0009){ref-type="ref"}, [10](#jah34752-bib-0010){ref-type="ref"} Although these findings highlight the importance of potassium disturbances as a risk factor for VF among MI patients,[11](#jah34752-bib-0011){ref-type="ref"} many of these studies were conducted in a time before the era of PPCI,[8](#jah34752-bib-0008){ref-type="ref"}, [9](#jah34752-bib-0009){ref-type="ref"}, [10](#jah34752-bib-0010){ref-type="ref"} included a relatively small number of patients,[8](#jah34752-bib-0008){ref-type="ref"}, [10](#jah34752-bib-0010){ref-type="ref"} and defined the outcome as cardiac arrest; therefore, a proportion of the arrests may not have been VF.[12](#jah34752-bib-0012){ref-type="ref"} Furthermore, none of these studies distinguished between STEMI and non‐STEMI patients. Both conditions arise from the same pathogenesis,[13](#jah34752-bib-0013){ref-type="ref"} but may not be comparable in risk assessment for VF as the burden of VF is lower among non‐STEMI patients (2%).[14](#jah34752-bib-0014){ref-type="ref"}, [15](#jah34752-bib-0015){ref-type="ref"}

Recently, in a large cohort of MI patients, a U‐shaped relationship between post‐admission potassium levels and in‐hospital mortality was observed and increased rates of cardiac arrest during hospitalization demonstrated for the lowest (\<3.0 mmol/L) and highest (≥5.0 mmol/L) potassium levels.[12](#jah34752-bib-0012){ref-type="ref"} However, this study was underpowered in regard to the number of VF, possibly because of misclassification of the cardiac arrest diagnosis. While recent studies have demonstrated prognostic effects of potassium disturbances in the inpatient setting,[12](#jah34752-bib-0012){ref-type="ref"}, [16](#jah34752-bib-0016){ref-type="ref"} no study has investigated the risk of potassium disturbances for developing VF in the early, and potentially modifiable, ischemic phase of an acute MI (before PPCI).

The aim of this study was to determine the association between potassium disturbances and the risk of VF before PPCI among STEMI patients. Since potassium disturbances may reflect a post‐resuscitation phenomenon, a sensitivity analysis was performed including STEMI patients with VF during PPCI who had potassium measurements before PPCI and, thereby, before VF.

Methods {#jah34752-sec-0009}
=======

Anonymized data created for the study are available in a persistent repository.

Study Design and Data Sources {#jah34752-sec-0010}
-----------------------------

This single‐center cohort study included patients aged ≥18 years with STEMI (Figure [1](#jah34752-fig-0001){ref-type="fig"}). Clinical data from the Eastern Danish Heart Registry were used. This registry comprises detailed clinical, angiographic, and procedural characteristics on all consecutive STEMI patients who underwent cardiac catheterization and coronary revascularization at Copenhagen University Hospital, Rigshospitalet since October 21, 1999. These data have been registered routinely by all operators and assistants in the catherization laboratory during percutaneous coronary intervention. Until June 1, 2011 Rigshospitalet had a catchment area for PPCI of 1.7 million inhabitants (30% of the entire Danish population), and from then on Rigshospitalet has covered all eastern Denmark corresponding to 2.5 million (45% of the entire Danish population).[5](#jah34752-bib-0005){ref-type="ref"}

![Flowchart illustrating the selection of patients with STEMI admitted to primary percutaneous coronary intervention at Rigshospitalet from 1999 to 2016. PPCI indicates primary percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.](JAH3-9-e014160-g001){#jah34752-fig-0001}

Data were linked to Danish nationwide administrative registries via the Civil Registration Number. All residents in Denmark receive a unique, personal, and permanent Civil Registration Number, which enables individual linkage of nationwide healthcare‐related registries unambiguously. Information on vital status and the date of birth was retrieved from the Danish Civil Registration System.[17](#jah34752-bib-0017){ref-type="ref"} The Danish National Patient Register holds information on all hospital admissions and outpatient contacts according to the *International Classification of Disease, Eighth and Tenth Revisions* (*ICD‐8* and *ICD‐10*),[18](#jah34752-bib-0018){ref-type="ref"} and the date of admission, discharge, and diagnoses was retrieved for every patient before the STEMI index admission (Table [S1](#jah34752-sup-0001){ref-type="supplementary-material"}). Information on dispensed medicine 3 months before the STEMI index was collected from the Danish National Prescription Registry, which holds information on all dispensed medical prescriptions from Danish pharmacies based on the Anatomical Therapeutic Chemical System codes including type of drug, dispensing date, strength, and quantity of all claimed drug prescriptions (Table [S2](#jah34752-sup-0001){ref-type="supplementary-material"}).[19](#jah34752-bib-0019){ref-type="ref"} Hypertension, diabetes mellitus, and hypercholesterolemia were identified according to diagnosis either from hospital admissions or outpatient contacts and in addition from dispensed medication (antihypertensives, antidiabetics, and cholesterol‐lowering drugs, respectively) 3 months before STEMI index.

Data on blood levels were obtained from an electronic laboratory database with several blood samples and their exact time of measurement. Blood samples immediately before PPCI were selected. Potassium levels were categorized in 3 preselected intervals: hypokalemia \<3.5 mmol/L, normokalemia 3.5--5.0 mmol/L, and hyperkalemia \>5.0 mmol/L.

Study Population {#jah34752-sec-0011}
----------------

To qualify for the study, patients had to have symptoms lasting ≤12 hours and acute ST‐segment elevation on an ECG. All patients underwent angiography and subsequent PPCI, and only the first admission to PPCI in patients with multiple admissions was considered.

The primary outcome was VF or sustained pulseless ventricular tachycardia (VT) (≥30 seconds and/or clinical cardiac arrest) within 12 hours of symptoms and before catheter insertion for PPCI. All medical reports and discharge summaries were reviewed to verify the VF diagnosis. Both out‐of‐hospital and in‐hospital cardiac arrest (but before PPCI) patients were included. Patients with out‐of‐hospital cardiac arrest were included upon admission to the PCI‐center after resuscitation by emergency medical service personnel. Patients with VF during PPCI were excluded from the main analysis as the arrhythmogenesis may be different and related to catheter maneuvers.

Since potassium levels were measured after VF but before PPCI, a sensitivity analysis was conducted to examine the association between potassium levels before VF and the risk of developing VF. STEMI patients with VF before PPCI were excluded and patients with VF during PPCI were identified, and they had potassium measurements immediately before PPCI and, thereby, before VF.

Statistical Analysis {#jah34752-sec-0012}
--------------------

The baseline and angiographic characteristics are presented as the median and interquartile range or proportion for the potassium groups. Statistical significance related to the descriptive differences were computed using the Wilcoxon rank‐sum test for continuous variables and the Chi‐square test (or Fisher exact test when appropriate) for categorical variables. A 2‐tailed *P*≤0.05 was considered statistically significant.

Logistic regression models were constructed to examine whether potassium disturbances were independent risk factors for VF among STEMI patients. Adjusted odds ratios (OR) and accompanying 95% confidence intervals (CI) were computed to estimate the associations. Multivariate logistic models were performed by including any covariate preceding the STEMI that is known to increase the risk of VF: age, sex, previous history of chest pain, smoking, hypertension, prior myocardial infarction, congestive heart failure, atrial fibrillation, acute creatinine levels, Killip class at admission, culprit lesion, and preprocedural thrombolysis in myocardial infarction (TIMI) flow.[5](#jah34752-bib-0005){ref-type="ref"}, [6](#jah34752-bib-0006){ref-type="ref"}, [20](#jah34752-bib-0020){ref-type="ref"}, [21](#jah34752-bib-0021){ref-type="ref"}, [22](#jah34752-bib-0022){ref-type="ref"} Peripheral vascular disease and diabetes mellitus were included in the model, as these comorbidities were independently associated with VF in this cohort. Smoking and Canadian Cardiovascular Society grading of angina pectoris were later removed from the model because of a large amount of missing information of 12% and 9%, respectively. Use of diuretic medication (loop diuretics, combinational diuretics, thiazides, and spironolactone) 3 months before STEMI index was also included. Prior use of antiarrhythmic therapy (class I and III agents) may reduce the risk of VF in the setting of STEMI. However, since \<0.2% of patients were treated with antiarrhythmic drugs 3 months before STEMI index, treatment with antiarrhythmic drugs was not included in the model. Finally, maximum troponin‐T levels measured during hospitalization (within 3 days after STEMI index) was included.

Additional analysis adjusted for age, sex, and acute creatinine levels was conducted to illustrate the relationship between potassium and VF before PPCI. The same potassium measurements and comparison groups were used but the hypokalemia group was divided into severe (2.1--2.7 mmol/L) and mild hypokalemia (2.8--3.4 mmol/L). The hyperkalemia group had too few patients to perform further substratification.

Furthermore, a subpopulation of STEMI patients with in‐hospital VF before PPCI was studied (excluding STEMI patients with out‐of‐hospital VF). In this way, the time window between VF and potassium measurement would be short and the VF anticipated to be treated immediately. A logistic regression model was performed to evaluate the association between potassium disturbances and risk of in‐hospital VF before PPCI adjusted for age, sex, and acute creatinine levels.

Finally, a logistic regression model was conducted in the sensitivity analysis to emphasize the association between potassium disturbances and VF during PPCI adjusted for age, sex, cardiovascular comorbidities (hypertension, prior myocardial infarction, congestive heart failure, atrial fibrillation, diabetes mellitus, and peripheral vascular disease), acute creatinine levels, maximum troponin‐T levels, Killip class, culprit lesion, preprocedural TIMI flow, and use of diuretic medication.

Analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC, USA) and RStudio (version 3.4).

Ethics Approval {#jah34752-sec-0013}
---------------

The study was approved by the Danish Data Protection Agency (2007‐58‐0015/GEH‐2014‐014 and I‐suite number: 02732). Registers were available in an anonymous setup; individual patients were not identifiable because the Civil Registration Numbers were encrypted. Approval from the Danish Patient Safety Authority was received to gain information on medical reports and discharge summaries (No. 3‐3013‐2277/1). In Denmark ethical approval is not required for retrospective register‐based studies.

Results {#jah34752-sec-0014}
=======

Out of 9446 consecutively enrolled STEMI patients, 8624 (91%) STEMI patients with potassium measurements immediately before PPCI were included, of whom 1797 (20.8%) had hypokalemia (\<3.5 mmol/L), 6693 (77.6%) had normokalemia \[3.5--5.0 mmol/L\], and 134 (1.6%) had hyperkalemia (\>5.0 mmol/L). The distribution of potassium approached that of a normal distribution with a mean of 3.8 mmol/L (SD: 0.5) (Figure [S1](#jah34752-sup-0001){ref-type="supplementary-material"}).

Clinical Characteristics {#jah34752-sec-0015}
------------------------

Among the 8624 included STEMI patients, 822 (9.5%) had VF before PPCI. Of the 822 STEMI with VF, 49 (6%) developed sustained pulseless VT. The majority had out‐of‐hospital cardiac arrest (77%) and 21% had in‐hospital cardiac arrest (2% with missing information).

Baseline and angiographic characteristics are summarized in Tables [1](#jah34752-tbl-0001){ref-type="table"} and [2](#jah34752-tbl-0002){ref-type="table"}. Compared with normokalemia, patients with hypokalemia were often women, smoked less, had fewer cardiovascular comorbidities, and lower acute creatinine levels. More often they had hypertension, used cardioactive drugs, had left anterior descending artery as culprit, and a preprocedural TIMI flow 0 to I.

###### 

Characteristics of Patients With STEMI Who Had Potassium Measurements Immediately Before Primary Percutaneous Coronary Intervention

  Variables                                                           Normokalemia 3.5 to 5.0 mmol/L (n=6693)   Hypokalemia \<3.5 mmol/L (n=1797)   *P* Value Hypokalemia Vs Normokalemia   Hyperkalemia \>5.0 mmol/L (n=134)   *P* Value Hyperkalemia Vs Normokalemia
  ------------------------------------------------------------------- ----------------------------------------- ----------------------------------- --------------------------------------- ----------------------------------- ----------------------------------------
  Male sex, n (%)                                                     5145 (76.9)                               1178 (65.6)                         \<0.001                                 99 (73.9)                           0.50
  Median age, y \[IQR\]                                               63.0 \[53.9, 71.9\]                       62.7 \[53.5, 72.0\]                 0.57                                    68.5 \[60.2, 76.9\]                 \<0.001
  Categorical age, n (%)                                                                                                                                                                                                        
  \<50 y                                                              1070 (16.0)                               302 (16.8)                          0.62                                    11 (8.2)                            0.003
  50 to 80 y                                                          4908 (73.3)                               1312 (73.0)                         99 (73.9)                                                                   
  ≥80 y                                                               715 (10.7)                                183 (10.2)                          24 (17.9)                                                                   
  Body mass index (BMI), kg/m^2^                                                                                                                                                                                                
  BMI ≥25, n (%)                                                      3270 (62.3)                               897 (64.5)                          0.14                                    59 (63.4)                           0.90
  Smoking, n (%)                                                                                                                                                                                                                
  Current                                                             3069 (52.3)                               762 (48.4)                          \<0.001                                 45 (47.4)                           0.62
  Past                                                                1480 (25.2)                               382 (24.3)                          27 (28.4)                                                                   
  Never                                                               1318 (22.5)                               430 (27.3)                          23 (24.2)                                                                   
  Canadian cardiovascular society grading of angina pectoris, n (%)                                                                                                                                                             
  Class I to II                                                       735 (12.1)                                182 (11.1)                          0.25                                    15 (14.7)                           0.50
  Class III to IV                                                     587 (9.7)                                 144 (8.8)                           7 (6.9)                                                                     
  No angina                                                           4753 (78.2)                               1316 (80.1)                         80 (78.4)                                                                   
  Comorbidities, n (%)                                                                                                                                                                                                          
  Diabetes mellitus                                                   789 (11.8)                                157 (8.7)                           \<0.001                                 41 (30.6)                           \<0.001
  Hypertension                                                        1692 (25.3)                               667 (37.1)                          \<0.001                                 62 (46.3)                           \<0.001
  Hypercholesterolemia                                                1220 (18.2)                               310 (17.3)                          0.36                                    35 (26.1)                           0.026
  Peripheral vascular disease                                         284 (4.2)                                 45 (2.5)                            \<0.001                                 14 (10.4)                           0.001
  Family history of ischemic heart disease                            1719 (32.5)                               466 (33.5)                          0.51                                    18 (28.6)                           0.60
  Ischemic heart disease                                              1356 (20.3)                               335 (18.6)                          0.14                                    39 (29.1)                           0.016
  Prior myocardial infarction                                         827 (12.4)                                177 (9.8)                           0.004                                   30 (22.4)                           \<0.001
  Congestive heart failure                                            312 (4.7)                                 64 (3.6)                            0.05                                    14 (10.4)                           0.004
  Atrial fibrillation                                                 290 (4.3)                                 71 (4.0)                            0.52                                    20 (14.9)                           \<0.001
  Stroke                                                              310 (4.6)                                 72 (4.0)                            0.28                                    9 (6.7)                             0.35
  Chronic kidney disease                                              194 (2.9)                                 39 (2.2)                            0.11                                    17 (12.7)                           \<0.001
  Liver disease                                                       87 (1.3)                                  29 (1.6)                            0.37                                    ≤3 (≤2.2)                           1.00
  Outcome, n (%)                                                                                                                                                                                                                
  Ventricular fibrillation before PPCI                                548 (8.2)                                 242 (13.5)                          \<0.001                                 32 (23.9)                           \<0.001
  Pharmacotherapy, n (%)                                                                                                                                                                                                        
  Diuretics (combinational)                                           265 (4.0)                                 187 (10.4)                          \<0.001                                 5 (3.7)                             1.00
  Loop diuretics                                                      292 (4.4)                                 82 (4.6)                            0.76                                    19 (14.2)                           \<0.001
  Thiazides                                                           357 (5.3)                                 256 (14.2)                          \<0.001                                 8 (6.0)                             0.90
  Spironolactone                                                      64 (1.0)                                  13 (0.7)                            0.43                                    9 (6.7)                             \<0.001
  Potassium supplements                                               210 (3.1)                                 98 (5.5)                            \<0.001                                 13 (9.7)                            \<0.001
  Renin‐angiotensin‐system blockers                                   1198 (17.9)                               386 (21.5)                          \<0.001                                 37 (27.6)                           0.005
  Beta‐blockers                                                       827 (12.4)                                208 (11.6)                          0.39                                    25 (18.7)                           0.040
  Anti‐adrenergic drugs                                               57 (0.9)                                  16 (0.9)                            0.99                                    0 (0.0)                             0.55
  Calcium channel blockers                                            728 (10.9)                                335 (18.6)                          \<0.001                                 20 (14.9)                           0.18
  Antidiabetics                                                       602 (9.0)                                 113 (6.3)                           \<0.001                                 33 (24.6)                           \<0.001
  Statins                                                             940 (14.0)                                224 (12.5)                          0.09                                    25 (18.7)                           0.16
  Antiarrhythmic drugs class I and III                                8 (0.1)                                   ≤3 (≤1.7)                           0.74                                    ≤3 (≤2.2)                           0.003
  Blood samples                                                                                                                                                                                                                 
  Acute creatinine, μmol/L \[IQR\]                                    78.0 \[66.0, 94.0\]                       76.0 \[64.0, 91.0\]                 \<0.001                                 126.5 \[97.0, 168.5\]               \<0.001
  Troponin‐T max, ng/L \[IQR\]                                        3775 \[1500, 7490\]                       3560 \[1360, 7520\]                 0.10                                    5110 \[1700, 13 300\]               0.007
  Time from symptom to troponin‐T max, h \[IQR\]                      13.8 \[9.6, 18.0\]                        13.9 \[9.8, 18.7\]                  0.15                                    15.5 \[9.1, 21.3\]                  0.23

Missing: BMI 22%, smoking 13%, family history of ischemic heart disease 22%, Canadian Cardiovascular Society class 9%, acute creatinine 7%, troponin‐T max 20%, and time from symptoms to troponin‐T max 20%. BMI indicates body mass index; IQR, interquartile range. STEMI indicates ST‐segment‐elevation myocardial infarction.

###### 

Angiographic and Procedural Characteristics of Patients With STEMI Who Had Potassium Measurements Immediately Before Primary Percutaneous Coronary Intervention

  Variables                                      Normokalemia 3.5 to 5.0 mmol/L (n=6693)   Hypokalemia \<3.5 mmol/L (n=1797)   *P* Value Hypokalemia Vs Normokalemia   Hyperkalemia \>5.0 mmol/L (n=134)   *P* Value Hyperkalemia Vs Normokalemia
  ---------------------------------------------- ----------------------------------------- ----------------------------------- --------------------------------------- ----------------------------------- ----------------------------------------
  Time from symptom onset to PPCI, min \[IQR\]   188 \[132--280\]                          145 \[108--230\]                    \<0.001                                 198 \[138--330\]                    0.21
  Preprocedural LVEF, n (%)                                                                                                                                                                                
  ≤35%                                           346 (26.1)                                107 (28.2)                          0.44                                    27 (64.3)                           \<0.001
  Infarct location, n (%)                                                                                                                                                                                  
  Anterior                                       2773 (44.6)                               808 (48.6)                          0.004                                   45 (42.1)                           0.67
  Non‐anterior                                   3445 (55.4)                               856 (51.4)                          62 (57.9)                                                                   
  Culprit lesion, n (%)                                                                                                                                                                                    
  LAD                                            2937 (44.1)                               864 (48.4)                          0.006                                   62 (46.6)                           0.84
  RCA                                            2748 (41.3)                               683 (38.2)                          53 (39.8)                                                                   
  LCX                                            970 (14.6)                                239 (13.4)                          18 (13.5)                                                                   
  Killip class, n (%)                                                                                                                                                                                      
  I                                              5841 (91.9)                               1572 (91.1)                         0.17                                    79 (64.8)                           \<0.001
  II                                             284 (4.5)                                 94 (5.4)                            10 (8.2)                                                                    
  III                                            87 (1.4)                                  28 (1.6)                            5 (4.1)                                                                     
  IV                                             146 (2.3)                                 31 (1.8)                            28 (23.0)                                                                   
  Preprocedural TIMI flow, n (%)                                                                                                                                                                           
  TIMI 0 to I                                    4245 (64.0)                               1209 (68.3)                         \<0.001                                 104 (78.8)                          \<0.001
  TIMI II to III                                 2392 (36.0)                               562 (31.7)                          28 (21.2)                                                                   
  Postprocedural TIMI flow, n (%)                                                                                                                                                                          
  TIMI 0 to I                                    163 (2.5)                                 45 (2.5)                            0.92                                    11 (8.3)                            \<0.001
  TIMI II to III                                 6462 (97.5)                               1727 (97.5)                         121 (91.7)                                                                  

Missing: Time from symptom to procedure 15%, LVEF 80%, and Infarct location 7%. IQR indicates interquartile range; LAD, left anterior descending artery; LCX, left circumflex artery; LVEF, left ventricular ejection fraction; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery, STEMI, ST‐segment--elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.

Patients with hyperkalemia were older, had more cardiovascular comorbidities, used more cardioactive and antidiabetic drugs, were in Killip class \>I, had pre‐ and post‐procedural TIMI flow 0 to I, and increased levels of acute creatinine and troponin‐T max compared with patients with normokalemia.

Multivariate Analysis {#jah34752-sec-0016}
---------------------

Younger age, male sex, atrial fibrillation, Killip class \>I, left anterior descending artery as culprit, and preprocedural TIMI flow 0 to I were all independent risk factors for VF, whereas prior myocardial infarction and diabetes mellitus were independently associated with reduced risk of VF (Table [3](#jah34752-tbl-0003){ref-type="table"}). Hypokalemia (OR 1.90, 95% CI 1.57--2.30, *P*\<0.001) and hyperkalemia (OR 3.36, 95% CI 1.95--5.77, *P*\<0.001) were associated with VF compared with normokalemia after adjusting for age, sex, cardiovascular comorbidities (hypertension, prior myocardial infarction, congestive heart failure, atrial fibrillation, diabetes mellitus, and peripheral vascular disease), acute creatinine levels, maximum troponin‐T levels, Killip class, culprit lesion, preprocedural TIMI flow, and use of diuretic medication (loop diuretics, combinational diuretics, thiazides, and spironolactone) (Figure [2](#jah34752-fig-0002){ref-type="fig"}).

###### 

A Logistic Regression Model of the Risk of VF Before PPCI in STEMI Patients

  Variables                       Contrast                   Odds Ratio   95% CI         *P* Value
  ------------------------------- -------------------------- ------------ -------------- -----------
  Blood samples                                                                          
  Hyperkalemia                    Normokalemia               3.36         1.95 to 5.77   \<0.001
  Hypokalemia                     Normokalemia               1.90         1.57 to 2.30   \<0.001
  Creatinine                      10 μmol/L of increase      1.00         1.00 to 1.01   \<0.001
  Troponin‐T max                  1000 ng/L of increase      1.01         1.00 to 1.02   0.24
  Age                                                                                    
  \<50 y of age                   ≥80 y of age               4.17         2.62 to 6.63   \<0.001
  50 to 80 y of age               ≥80 y of age               3.94         2.59 to 5.99   \<0.001
  Sex                             Men vs women               1.29         1.04 to 1.60   0.020
  Hypertension                    Yes vs no                  1.14         0.89 to 1.45   0.29
  Prior myocardial infarction     Yes vs no                  0.73         0.53 to 1.00   0.048
  Congestive heart failure        Yes vs no                  0.60         0.35 to 1.02   0.06
  Atrial fibrillation             Yes vs no                  1.62         1.08 to 2.42   0.019
  Diabetes mellitus               Yes vs no                  0.55         0.40 to 0.75   \<0.001
  Peripheral vascular disease     Yes vs no                  1.72         1.14 to 2.59   0.009
  Killip class \>I at admission   Killip class I             2.95         2.30 to 3.77   \<0.001
  Culprit                         LAD vs non‐LAD             1.58         1.32 to 1.87   \<0.001
  Preprocedural TIMI flow         TIMI 0 to I vs II to III   1.33         1.10 to 1.62   0.004
  Loop diuretics                  Yes vs no                  1.10         0.68 to 1.78   0.70
  Combinational diuretics         Yes vs no                  0.82         0.54 to 1.23   0.33
  Thiazides                       Yes vs no                  1.05         0.74 to 1.49   0.80
  Spironolactone                  Yes vs no                  1.56         0.65 to 3.71   0.32

LAD indicates left anterior descending artery; PPCI, primary percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction; VF, ventricular fibrillation.

![Potassium disturbances associated with ventricular fibrillation before primary percutaneous coronary intervention among patients with STEMI who had potassium measurements immediately before primary percutaneous coronary intervention. PPCI indicates primary percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; VF, ventricular fibrillation.](JAH3-9-e014160-g002){#jah34752-fig-0002}

A U‐shaped relationship between potassium levels and VF before PPCI was found with the highest risk for VF among patients with severe hypokalemia \[2.1--2.7 mmol/L\] compared with normokalemia after adjusting for age, sex, and acute creatinine levels (Figure [3](#jah34752-fig-0003){ref-type="fig"}).

![Association between potassium levels and risk of ventricular fibrillation before primary percutaneous coronary intervention among patients with STEMI. The x axis shows potassium measurements (mmol/L) immediately before primary percutaneous coronary intervention. The y axis shows the odds ratio of ventricular fibrillation before primary percutaneous coronary intervention adjusted for age, sex, and acute creatinine level. Each point indicates the odds ratio corresponding to the median of potassium for 4 potassium intervals: severe hypokalemia \[2.1--2.7 (mmol/L); 4.61, 95% CI 2.77--7.42\], mild hypokalemia \[2.8--3.4 (mmol/L); odds ratio=1.76, 95% CI 1.48--2.09\], normokalemia \[3.5--5.0 (mmol/L); reference\], hyperkalemia \[5.1--7.4 (mmol/L); odds ratio 2.76, 95% CI 1.74--4.26\]. The horizontal bars indicate the range of the potassium levels. The vertical bars indicate the 95% CI of the odds ratios. PPCI indicates primary percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; VF, ventricular fibrillation.](JAH3-9-e014160-g003){#jah34752-fig-0003}

Finally, a subpopulation of patients with in‐hospital VF before PPCI was studied. Among the 7977 included STEMI patients without out‐of‐hospital VF, 175 (2.2%) had in‐hospital VF before PPCI. Hypokalemia (n=1616) (OR 2.23, 95% CI 1.60--3.11, *P*\<0.001) was associated with VF compared with normokalemia after adjusting for age, sex, and acute creatinine level (Table [S3](#jah34752-sup-0001){ref-type="supplementary-material"}). For hyperkalemia (n=104) (OR 0.79, 95% CI 0.17--3.61, *P*=0.76), no significant association was found (Table [S3](#jah34752-sup-0001){ref-type="supplementary-material"}).

Sensitivity Analysis {#jah34752-sec-0017}
--------------------

The sensitivity analysis included 7929 STEMI patients without VF before PPCI of whom 127 (1.6%) had VF during PPCI. Baseline and angiographic characteristics are shown in supplementary Tables [S4 and S5](#jah34752-sup-0001){ref-type="supplementary-material"}. Patients with hypokalemia were often women, smoked less, had fewer cardiovascular comorbidities (except for hypertension), used more antihypertensive drugs, and had lower acute creatinine levels, whereas patients with hyperkalemia were older, had more cardiovascular comorbidities, and used more medications compared with normokalemia. Compared with normokalemia, patients with hypokalemia had an OR of 1.68 (95% CI 1.01--2.77, *P*=0.045) and patients with hyperkalemia had an OR of 3.23 (95% CI 0.99--10.50, *P*=0.05) for VF after adjustment (Figure [4](#jah34752-fig-0004){ref-type="fig"}, and Table [S6](#jah34752-sup-0001){ref-type="supplementary-material"}).

![Potassium disturbances associated with ventricular fibrillation during PPCI among patients with STEMI who had potassium measurements immediately before primary percutaneous coronary intervention. PPCI indicates primary percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction, VF, ventricular fibrillation](JAH3-9-e014160-g004){#jah34752-fig-0004}

Discussion {#jah34752-sec-0018}
==========

In this study with consecutive data collected from 1999 to 2016, 8624 STEMI patients were enrolled, of whom 822 (9.5%) developed VF before PPCI. Increased risk of VF before PPCI was demonstrated for patients with hypokalemia \[\<3.5 mmol/L\] and hyperkalemia \[\>5.0 mmol/L\], and a U‐shaped relationship between potassium levels and VF before PPCI was found, with the highest risk of VF among patients with severe hypokalemia \[2.1--2.7 mmol/L\].

Whereas patients with VF before PPCI had potassium measurements after VF that may be disturbed by the VF itself, patients with VF during PPCI had potassium measurements before VF. Importantly, hypokalemia was associated with increased risk of VF during PPCI. Hence, the association between hypokalemia and VF may be independent of the measurement of potassium before or after VF.

To the best of our knowledge, this is the first comprehensive study to investigate the association between potassium disturbances and the risk of VF before PPCI. In addition to an increased risk for VF in patients with severe hypo‐ and hyperkalemia, our data suggested that patients with mild hypokalemia also had a higher risk for VF. Mild hypokalemia \[2.8--3.4 mmol/L\] is not always considered harmful in daily clinical practice and may not be a target for immediate intervention. These findings suggest that maintenance of potassium levels between 3.5--5.0 mmol/L is advisable as currently recommended by practice guidelines in patients with AMI based on non‐randomized trials.[23](#jah34752-bib-0023){ref-type="ref"}

Recently, Goyal and colleagues[12](#jah34752-bib-0012){ref-type="ref"} investigated the correlation between mean post‐admission potassium levels and mortality rates among MI patients. They found a U‐shaped relationship between in‐hospital mortality and potassium levels with the lowest risk between 3.5 and \<4.5 mmol/L. Compared with mortality risk, they observed a relatively more flattened association between potassium levels and the risk of cardiac arrest during hospitalization. They found a significant increase in the risk of cardiac arrest for patients with hypokalemia \<3.0 mmol/L after adjustment for age, sex, and glomerular filtration rate at admission. However, the number of events (cardiac arrest because of any cause) in the hypokalemia group was low (n=5), perhaps because of misclassification of the cardiac arrest diagnosis.

In this study, patients with hypokalemia had a lower burden of cardiovascular comorbidities, whereas hypertension and use of cardioactive drugs were more frequent compared with normokalemia, eg, thiazides which can cause pronounced hypokalemia during MI.[24](#jah34752-bib-0024){ref-type="ref"} Importantly, after adjusting for use of any diuretics, the risk estimates for both hypo‐ and hyperkalemia remained unchanged.

Both endogenous epinephrine attributable to the cardiac arrest and exogenous epinephrine administered during resuscitation can transiently cause hypokalemia and decrease potassium by as much as 1 mmol/L.[25](#jah34752-bib-0025){ref-type="ref"} Since potassium was measured after VF in the main analysis, hypokalemia may reflect a post‐resuscitation phenomenon. However, in the sensitivity analysis, increased risk of VF was demonstrated for patients with hypokalemia measured before VF. Thus, the association between hypokalemia and VF may be independent of the measurement of potassium before or after VF. Moreover, additional analysis was performed including 175 patients with VF before PPCI in whom VF occurred after admission to the hospital. In this way, the time window between VF and potassium measurement would be short and the VF anticipated to be treated immediately. Compared with patients with normokalemia, patients with hypokalemia had increased risk of in‐hospital VF before PPCI after adjusting for age, sex, and acute creatinine level. Patients with hyperkalemia had no increased risk of VF possibly because of lack of power (n≤3).

Patients with hyperkalemia had more cardiovascular comorbidities and higher use of various medications. Hence, hyperkalemia may be a marker of comorbidities and polypharmacy. Furthermore, acidosis following cardiac arrest or cardiogenic shock stimulates cellular efflux of potassium leading to hyperkalemia,[26](#jah34752-bib-0026){ref-type="ref"} and patients with hyperkalemia were often Killip class \>I. As epinephrine can lead to hypokalemia, a larger fraction of patients with hyperkalemia would be found in the normokalemia group. Hence, the risk estimates for VF among patients with hyperkalemia may be even greater than reported herein.

Prior myocardial infarction and diabetes mellitus was independently associated with reduced risk of VF before PPCI among patients with STEMI. This is a departure from our usual understanding.[20](#jah34752-bib-0020){ref-type="ref"}, [27](#jah34752-bib-0027){ref-type="ref"} A possible explanation for this is that these patients may have more severe coronary artery disease which may influence the formation of collateral blood flow. However, data are conflicting whether diabetes mellitus enhance or impair the formation of collateral blood flow.[28](#jah34752-bib-0028){ref-type="ref"}, [29](#jah34752-bib-0029){ref-type="ref"} Furthermore, recent studies suggest that the increase in risk of sudden cardiac arrest among patients with diabetes mellitus is not specific for sudden cardiac arrest, as diabetes mellitus also is associated with a similar increase in risk of death because of fatal (non‐sudden cardiac arrest) coronary heart disease, and non‐fatal myocardial infarction.[30](#jah34752-bib-0030){ref-type="ref"}, [31](#jah34752-bib-0031){ref-type="ref"} Hence, patients with diabetes mellitus may not be at greater risk of VF in the setting of STEMI. On the other hand, as patients who do not survive to reach the hospital or who do not undergo PPCI are not included in this study, a proportion of patients with prior myocardial infarction and diabetes mellitus may not be included.

Strengths and Limitations {#jah34752-sec-0019}
-------------------------

The strength of this study is the completeness of data via link between clinical data (the Eastern Danish Heart Registry) and Danish nationwide registries. Furthermore, this study was well‐powered as the cohort was large, patients were enrolled consecutively, and the phenotype was refined by enrolling only STEMI patients with VF and distinguishing between VF before and during PPCI. Even though data were prospectively collected, a retrospective analysis was performed. Patients who died outside of hospitals were not included, and the results may not be generalizable to patients who do not survive to reach the hospital or who do not undergo angiography.

Given that the majority of patients had an out‐of‐hospital cardiac arrest (77%), quite a few variables were unaccounted for eg, medications given in the field by the emergency medical services personnel during resuscitation and time to return of spontaneous circulation which may have had an effect on the in‐patient potassium levels.

Only absolute values for potassium levels were included and not fluctuations, which may be more accurate.[32](#jah34752-bib-0032){ref-type="ref"} Information on smoking status, Canadian Cardiovascular Society grading of angina pectoris, pre‐procedural left ventricular ejection fraction, and magnesium levels in blood samples were missing for 12%, 9%, 80%, and 95% of patients, respectively, and thus could not be considered in the model. QT dispersion plays an important role for the pathophysiology of VF and/or polymorphic VT, however, information on QTc intervals from the ECG was not available and therefore adjustments could not be performed. Nevertheless, previously, in a subset of the cohort, no difference in QTc intervals was measured between STEMI patients with or without VF before PPCI.[6](#jah34752-bib-0006){ref-type="ref"} This is in line with the findings of others.[33](#jah34752-bib-0033){ref-type="ref"}, [34](#jah34752-bib-0034){ref-type="ref"}

In the sensitivity analysis, patients with hyperkalemia did not have an increased risk of VF during PPCI possibly because of a lack of power. Moreover, VF during PPCI may be propagated by extensive manipulation (catheter maneuvers), coronary spasms, and reperfusion of the coronary artery and thus differ from the pathogenesis of VF before PPCI.

Clinical Implications {#jah34752-sec-0020}
---------------------

In the future, potassium measurements performed prehospital in the ambulance by arterial blood gas analysis would allow early detection and the opportunity for correction of potassium disturbances. This may reduce the risk of VF and subsequent death during acute ischemia. Further studies are needed to determine if correcting potassium disturbances among patients with STEMI will reduce the risk of VF.

Conclusions {#jah34752-sec-0021}
===========

Hypokalemia and hyperkalemia are associated with increased risk of VF in the early phase of STEMI (before PPCI). For hypokalemia, the association may be independent of the measurement of potassium before or after VF.
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